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Abstract
Background: Metastasis is the leading cause of cancer-related death. Bone marrow (BM) is a
frequent site for the settlement of disseminated tumor cells which occurs years before overt
metastases signal incurability.
Methods: Here we describe a new method to assess the initial stage of metastasis development
in cancer patients. By immunomagnetic selection with HER2/neu and EpCAM as catcher antigens
single disseminated tumor cells can be enriched from BM samples. To examine whether the
immunomagnetic enrichment technique may change gene expression in the selected tumor cells,
we performed differential expression profiling with the breast cancer cell lines MCF-7 and BT474
as models. The profiles were performed using 1.2 Cancer Arrays (Clontech) containing 1176
cDNAs that can be grouped into different functional categories, such as signal transduction, cell
cycle, adhesion, cytoskeleton plasticity, growth factors and others.
Results: The reproducibility of the gene expression profiling between duplicate cDNA-array
experiments was assessed by two independent experiments with MCF-7 breast cancer cells.
Scatter blot analysis revealed a good reproducibility of the cDNA array analysis (i.e. less than 10%
difference in the gene expression between the arrays). Subsequent comparative cDNA-array
analyses of immunobead-selected and unselected MCF-7 and BT474 cancer cells indicated that the
antibody incubation during the immunomagnetic selection procedure did not considerably alter the
gene expression profile.
Conclusion: The described method offers an excellent tool for the enrichment of micrometastatic
tumor cells in BM without largely changing the gene expression pattern of these cells.
Introduction
Solid tumors derived from epithelial organs are the main
form of cancer in industrialized countries. The first phase
of the metastatic development consists of local tumor cell
invasion, followed by tumor cell circulation in the blood
and homing to secondary distant organs [1,2]. As indica-
tor organ for early systemic dissemination of epithelial
tumor cells to distant sites, BM has played a prominent
role [3]. BM can easily be aspirated from the iliac crest and
single metastatic cells are already present in 20–40% of
patients with epithelial tumors (e.g., breast, lung or colon
carcinomas) years before overt distant metastases occur in
the skeleton or other distant organs [3-5]. The molecular
description of these cells has been, however, hampered by
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the low concentration of these cells (e.g., 10-5-10-6 per BM
cell). To predict and monitor therapeutic responses the
assessment of the gene expression profile of disseminated
tumor cells seems to be of utmost importance. However,
it is uncertain to which extent incubation with antibodies
used for immunomagnetic isolation of these cells might
affect their expression profile. We have addressed this
aspect, using monoclonal antibodies against two promi-
nent antigens, EpCAM and HER2/neu that are frequently
and independently expressed on micrometastatic tumor
cells [3].
Materials and methods
Ficoll density gradient centrifugation and 
immunocytochemistry
The enrichment of tumor cells from BM by Ficoll density
gradient centrifugation and the immunocytochemical
detection of epithelial tumor cells in cytological BM prep-
arations has been described elsewhere in detail [5,6].
Immunomagnetic cell separation and 
immunocytochemistry of BM samples
Two ml of a BM sample usually containing 2 × 106 mono-
nuclear cells were washed with Hank's Salt Solution (Bio-
chrom KG, Germany). The pellet was resuspended in 2 ml
Hanks and 3.2 × 107 (80 µl) CELLection™ and pan-mouse
immunomagnetic beads (Dynal, Oslo, Norway) coated
with anti-EpCAM (MAb 3B10) and anti-HER2/neu (MAb
7C1) antibodies (Micromet, Munich, Germany) were
added. All solutions and cell preparations were kept at
4°C during the whole procedure to avoid nonspecific
binding of immunomagnetic beads. After an incubation
time of 30 min at 4°C and 20 min at room temperature
on a rotating mixer the magnetically labeled cells were iso-
lated in a magnetic particle concentrator and resuspended
in 200 µl bead removing buffer (40 mM Tris, 10 mM
MgSO4, and 1 mM CaCl2, pH7.4, prewarmed to room
temperature). The immunomagnetic beads were removed
by DNase treatment with 15 µl DNase (50 U/µl) at room
temperature for 15 min. After separation in a magnetic
particle concentrator the supernatant was collected and
centrifuged onto glass slides. Tumor cells were identified
by immunostaining with monoclonal anti-cytokeratin
antibody A45-B/B3 according to the manufacturer's
instruction (Micromet, Munich, Germany). Cytokeratins
are specific constituents of the epithelial cytoskeleton and
they have become the marker antigen of choice for the
detection of disseminated epithelial tumor cells in mesen-
chymal organs such as BM [3,7]. To avoid unspecific bind-
ing of the antibody via Fc-receptors present on leukocytes,
we used Fab fragments of A45-B/B3 that were directly con-
jugated to the marker enzyme alkaline phosphatase.
Cell culture and antibody incubation
MCF-7 cells and BT474 cells were maintained in RPMI
(Invitrogen, Karlsruhe, Germany) supplemented with 5 %
glutamine (Invitrogen) and 10 % FCS (C-C Pro, Neustadt,
Germany). MCF-7 and BT474 cells (ATCC HTB-22 and
HTB-20) were allowed to reach a logarithmic growth
phase in culture. At 90 % confluency, the cells were incu-
bated for 30 min at 4°C and 20 min at room temperature
in Hanks containing 1 µg/ml of anti-EpCAM (MAb 3B10)
as well as anti-HER2/neu (MAb 7C1) antibodies accord-
ing to the immunomagnetic cell separation protocol. In a
negative control experiment, cells were suspended in
Hanks devoid of antibodies.
cDNA probe preparation and hybridization
Total RNA was isolated using the peqGold TriFast™
(Peqlab, Erlangen, Germany) according to the manufac-
turer's instruction. In order to remove genomic DNA con-
tamination, a DNase step was included using the DNA-
free™ kit (Ambion, Cambrigeshire, England) according to
manufacturer's instructions. RNA was dissolved in RNase-
free H2O with 1 U/µl RNase inhibitor (SUPERase. IN™,
Ambion). 5 µg purified total RNA was used for [α -33P]
dATP (3000 Ci/mmol, 10 µl; Amersham, Freiburg, Ger-
CK-positive cells detected after immunomagnetic enrich- ment of BM from breast cancer patients Figure 1
CK-positive cells detected after immunomagnetic enrich-
ment of BM from breast cancer patients. One single cell and 
one 2-cell cluster is shown in a 400× magnification.Journal of Translational Medicine 2005, 3:12 http://www.translational-medicine.com/content/3/1/12
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many) labeled cDNA synthesis as previously described
[8]. The cDNA probe was purified with nucleotide
removal columns (Qiagen, Hilden, Germany). The Atlas
Human 1.2 Cancer Arrays (Clontech, Heidelberg, Ger-
many) were hybridized according to the manufacturer's
protocol.
cDNA- array data analysis
The membranes were exposed to phosphoimager plates
(Raytest Isotopen-Meβ geräte, Straubenhardt, Germany)
for 3 days, and plates were scanned with the phosphoim-
ager Fuji Bas (Raytest) at a 100 µm-resolution. The images
were analyzed using the Imagene 5.5 software (Biodiscov-
ery, CA, USA). The data of the arrays were normalized on
the basis of the genes ubiquitin, HLAC and beta actin. The
ratio between antibody-treated and non-treated cells was
calculated for each gene. Ratios lower than 0.5 or higher
than 2 were considered as differentially expressed if at
least one sample showed an expression above 0.5. We per-
formed duplicates of each experiment and created scatter
blots with the SPSS software for windows.
Results
In a recent work [9] we demonstrated that our immu-
nomagnetic separation works on clinical samples (Figure
1) and is superior to the standard Ficoll density centrifu-
gation technique, used in most previous studies on cancer
micrometastasis [4,5,7,10].
Representative scatter blots of breast cancer cells using the 1.2 Cancer Array for expression analysis Figure 2
Representative scatter blots of breast cancer cells using the 1.2 Cancer Array for expression analysis. (A) untreated MCF-7 
breast cancer cells (results of duplicate experiments), (B) antibody-treated versus untreated MCF-7 cells, and (C) antibody-
treated versus untreated BT474 breast cancer cells.Journal of Translational Medicine 2005, 3:12 http://www.translational-medicine.com/content/3/1/12
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Table 1: Genes differentially expressed in antibody-treated versus untreated BT474 cell
Genes GenBank Accession# Ratio*
Extracellular matrix remodeling:
COL11 J04177 - 6.2
MMP17 X89576 - 4.7
MMP16 D50477 -4.6
SPARC J03040 5.7
Adhesion:
PKD1 U24497 - 7.3
NCAM AF002246 7.3
M-cadherin D83542 3.5
Cytoskeleton plasticity:
SPTA1 M61877 7.4
Signal transduction:
RGS4 U27768 - 10.1
GAS L13720 - 7.1
BMP1 U50330 - 7.0
FGFR4 L03840 - 6.5
PMEL17 M77348 - 6.5
ETS-1 - 5.9
ERBB2 M95667 - 5.8
TGF-beta X02812 - 5.2
N-ras X02751 - 4.8
HRS D84064 - 4.7
KIR U10550 9.0
BMP6 M60315 7.5
BIN1 U68485 7.4
SGI Y00064 4.1
CDC7 AF015592 3.8
CNTF S72921 3.4
SH3BP2 AF000936 3.1
Apoptosis:
CD27BP U82938 6.0
DR5 F016268 4.8
Metabolism:
PPAT U00238 6.3
HPRT P00492 5.4
Immune response:
MHC class I U65416 8.4
Replication/repair/transcription:
CHAF1A U20979 - 12.3
NEK3 Z29067 - 5.6
BTG U72649 8.9
HRC1 M91083 6.2
TOP1 J03250 4.9
CLK1 L29222 4.0
Functionally unclassified
PIG7 AF010312 - 4.9
menin U93236 3.1
*Ratio of normalized data from antibody-treated versus untreated BT474 cells as described in the Materials and Methods section. Negative values 
indicate downregulated and positive values upregulated genes.Journal of Translational Medicine 2005, 3:12 http://www.translational-medicine.com/content/3/1/12
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To test whether the antibody incubation during the
immunomagnetic enrichment approach affects gene
expression in the selected cells, we applied cDNA-array
analysis. We subsequently evaluated whether the immu-
nomagnetic enrichment method affected gene expression
in the selected cells. This aspect is of utmost importance
for further molecular description of disseminated tumor
cells and has not been addressed before. The profiles were
performed using 1.2 Cancer Arrays (Clontech) containing
1176 cDNAs that can be grouped into different functional
categories, such as signal transduction, cell cycle, adhe-
sion, cytoskeleton plasticity, growth factors and others
[11].
As models, we used the breast cancer cell lines MCF-7 and
BT474 (ATCC HTB-22 and HTB-20), because they express
heterogeneous levels of the target antigens HER2/neu and
EpCAM comparable to micrometastatic breast cancer cells
in vivo [3]. The reproducibility of the gene expression pro-
filing between duplicate cDNA-array experiments was
assessed by two independent experiments with MCF-7
breast cancer cells. As shown in Figure 2A, scatter blot
analysis revealed a good reproducibility of the cDNA array
analysis (i.e. less than 10% difference in the gene expres-
sion between the arrays). We plotted the data of the anti-
body-treated and untreated MCF-7 (B) or BT474 (C) cells
two dimensionally in a scatter plot; y-axis represents the
data of untreated cells and the x-axis represents the data of
cells treated with anti-HER2/neu or anti-EpCAM. For both
cell lines, the scatter plots show that expressed genes in
antibody-treated versus untreated cells (Figure 2B, C) was
in principal within the range observed in the duplicate
experiments with MCF-7 cells (Figure 2A). However, sub-
tle changes in the expression of individual genes after anti-
body incubation were observed in particular in BT474
cells. In this cell line 38 genes were strongly differentially
expressed (ratio >3) in antibody-treated versus untreated
cells (Table 1). Most of these genes play a role in extracel-
lular matrix remodeling, signal transduction and replica-
tion, as well as repair and transcription. MCF-7 cells
showed in this experimental approach 31 differentially
expressed genes with a ratio of over 3 (data not shown).
Although similar group of genes were affected, only 3
common genes (CDC7, SGI and KIR) were differentially
expressed in both cell lines after antibody incubation.
Discussion
Here, we investigated whether an immunomagnetic
enrichment procedure for micrometastatic cancer cells
present in BM aspirates leads to significant changes in the
gene expression pattern of the enriched tumor cells. In
order to mimic the biological conditions of a tumor type
with frequent BM involvement, we used two breast cancer
cell lines (MCF-7 and BT474). Both cell lines expressed
the target antigens, EpCAM and HER2/neu, for immu-
nomagnetic separation at different levels [12] and they
were incubated with the anti-EpCAM and anti-HER2/neu
antibodies according to the same immunomagnetic
enrichment protocol used for the BM samples from cancer
patients analyzed recently [9]. It has been shown by other
groups that some of the mAb directed against HER2/neu
(e.g., HerceptinR) can specifically block cell proliferation
and affect gene expression in HER2/neu-positive breast
cancer cells [13,14]. Furthermore the incubation of
human cells with anti-EpCAM-specific mAbs (e.g. KS1/4
mAb) can induce considerable changes in the expression
of insulin and glucagons [15]. However, our present
results suggest that the two antibodies against EpCAM and
HER2/neu used for the immunomagnetic selection proc-
ess did not considerably influence the gene expression
pattern of the enriched cells, although the HER2/neu-
positive cell line showed a slightly increased number of
differentially expressed genes. These genes are involved in
extracellular matrix remodeling, signal transduction and
replication, repair and transcription, and they were either
up or downregulated after antibody incubation. For exam-
ple, HER2/neu gene expression was downregulated after
antibody binding, as expected from reports in the litera-
ture [16]. Taken together, we cannot exclude subtle
changes in the expression of individual genes after
antibody incubation, but we observed no obvious shift in
the expression pattern that exceeds the normal variability
of duplicate experiment.
Thus, we conclude that the immunomagnetic selection
protocol described here might be useful for experimental
approaches aimed to determine the gene expression pro-
file and genome of disseminated CK-positive cells
[17,18]. As we performed our study only on two breast
cancer cell lines, larger series of similar experiments with
further cancer cell lines as well as with enriched tumor
cells from the blood or BM must be investigated to draw
firm conclusions. The detection and characterization of
micrometastatic cancer cells will provide new insights into
the biology of the metastatic process in cancer patients.
This will lead to an improved molecular staging of cancer
patients and to the identification of new biological targets
for adjuvant systemic therapies aimed to eradicate
micrometastatic disease before the onset of overt metasta-
sis signals incurability.
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